[1] 廖光东, 康乐妮, 李静, 等. p16/微小染色体维持蛋白2和p16/Ki-67双重染色对高危型人乳头瘤病毒呈阳性妇女的宫颈病变筛查[J]. 中华妇幼临床医学杂志(电子版), 2017, 13(4):425-431. [2] 杨秀玮, 张路伟, 周亮, 等. 用DNA倍体分析方法判断宫颈癌前病变的发展趋势[J]. 中国组织化学与细胞化学杂志, 2018, 27(4):354-358. [3] WRIGHT T C JR, BEHRENS C M, RANGER-MOORE J, et al. Triaging HPV-positive women with p16/Ki-67 dual-stained cytology:Results from a sub-study nested into the ATHENA trial[J]. Gynecol Oncol, 2017, 144(1):51-56. [4] 刘玉艳, 沈久洋, 朱安超, 等. P16/Ki-67细胞学双染在子宫颈癌筛查中应用价值[J]. 临床与实验病理学杂志, 2017, 33(1):38-41. [5] 周琦, 吴小华, 刘继红, 等. 宫颈癌诊断与治疗指南(第四版)[J]. 中国实用妇科与产科杂志, 2018, 34(6):613-622. [6] YU L L, CHEN W, LEI X Q, et al. Evaluation of p16/Ki-67 dual staining in detection of cervical precancer and cancers:a multicenter study in China[J]. Oncotarget, 2016, 7(16):21181-21189. [7] EBISCH R M, VAN DER HORST J, HERMSEN M, et al. Evaluation of p16/Ki-67 dual-stained cytology as triage test for high-risk human papillomavirus-positive women[J]. Mod Pathol, 2017, 30(7):1021-1031. [8] GAGE J C, HUNT W C, SCHIFFMAN M, et al. Risk stratification using human papillomavirus testing among women with equivocally abnormal cytology:results from a state-wide surveillance program[J]. Cancer Epidemiol Biomarkers Prev, 2016, 25(1):36-42. [9] 张云清, 尹香利, 韩慧慧, 等. TCT与DNA倍体分析对早期宫颈癌联合筛查的临床研究[J]. 中国医刊, 2018, 53(5):550-553. [10] 高亮, 陈娥华, 王少娜, 等. FE染色及DNA倍体分析技术在宫颈癌早期筛查中的应用[J]. 中国妇幼保健, 2018, 33(9):2100-2103. [11] ZIEMKE P. P16/ki-67 immunocytochemistry in gynecological cytology:limitations in practice[J]. Acta Cytol, 2017, 61(3):230-236. [12] 彭端亮, 刘成桂, 邓耀, 等. HPV DNA检测在宫颈病变筛查中的价值[J]. 重庆医学, 2017, 46(29):4067-4069. [13] 贾惠, 翟红岩, 冯燕, 等. DNA倍体定量分析在宫颈癌筛查中的临床应用研究[J]. 中国临床医生杂志, 2017, 45(9):94-96. [14] TAY T K Y, LIM K L, HILMY M H, et al. Comparison of the sensitivity and specificity of p16/Ki-67 dual staining and HPV DNA testing of abnormal cervical cytology in the detection of histology proven cervical intraepithelial neoplasia grade 2 and above (CIN 2+)[J]. Malays J Pathol, 2017, 39(3):257-265. [15] 吴煜, 欧红. 机会性宫颈癌筛查中DNA倍体分析的临床价值探究[J]. 中国医疗设备, 2017(Sup 1):208. [16] 王海瑞, 廖光东, 陈汶, 等. P16/Ki-67免疫细胞化学双染在宫颈癌筛查中的应用价值[J]. 中华肿瘤杂志, 2017, 39(8):636-640. [17] ROBIAL R, LONGATTO-FILHO A, ROTELI-MARTINS C M, et al. Frequency of Chlamydia trachomatis infection in cervical intraepithelial lesions and the status of cytological p16/Ki-67 dual-staining[J]. Infect Agents Cancer, 2017, 12:3. [18] 钱晓月, 陈飞, 尤志学. 免疫细胞化学p16/Ki-67双染色法在子宫颈癌筛查中应用的研究进展[J]. 中华妇产科杂志, 2017, 52(11):792. [19] 张金秋, 朱萍, 陆敏华, 等. 细胞免疫化学p16/Ki-67双染结合DNA倍体分析预测HSIL的研究[J]. 重庆医学, 2017, 46(13):1770-1772. [20] PACKET B, POPPE W, WEYNAND B, et al. The use of p16/Ki-67 dual staining technology on cervical cytology of patients undergoing a LLETZ procedure[J]. Eur J Obstet Gynecol Reprod Biol, 2018, 228:191-196. [21] 刘峰, 张春霞, 张莉, 等. 宫颈癌及癌前病变中Ki-67、P16蛋白的表达差异及诊断价值[J]. 中国临床医学, 2018, 25(2):278-281. |